Arbutus Biopharma Corp
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-19.8M | $-17.9M | $-19.3M | $-20.1M | $-17.1M | $-16.3M | $-21.9M | $-17.6M |
| Depreciation & Amortization | $356.0K | $355.0K | — | $369.0K | $342.0K | $334.0K | — | $343.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $3.2M | $2.0M | $1.7M | $2.5M | $3.0M | $2.1M | $1.7M | $1.7M |
| Net Cash from Operating Activities | $-14.5M | $-19.3M | $-17.3M | $-21.8M | $-19.6M | $-27.3M | $-17.0M | $-18.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $1.0K | $95.0K | $0 | $32.0K | $859.0K | $117.0K | $134.0K | $91.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $9.8M | $11.7M | $22.2M | $10.4M | $1.4M | $16.7M | $12.7M | $-13.7M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $24.4M | $24.4M | $3.8M | $1.7M | $4.7M | $20.4M | $11.1M | $9.1M |
| Net Change in Cash | $19.7M | $16.8M | $8.8M | $-9.7M | $-13.4M | $9.8M | $6.8M | $-23.3M |
| Free Cash Flow | $-14.5M | $-19.4M | $-17.3M | $-21.8M | $-20.4M | $-27.4M | $-17.1M | $-18.8M |